N-terminal pro-brain natriuretic peptide (NT-proBNP) and sRAGE levels in early rheumatoid arthritis
Authors' conclusion
Suppressing inflammation, independently of achieving remission, increases sRAGE levels and decreases NT-proBNP levels significantly.
Study context
- Population
- Consecutive early rheumatoid arthritis (RA) patients participating in the 'Parelsnoer' cohort
- Participants
- 342 patients
- Exposure
- Baseline vs 6 months of anti-rheumatic treatment
- Outcome
- Associations between NT-proBNP and sRAGE levels and markers of inflammation and disease activity, and their changes during anti-rheumatic treatment
- Follow-up
- 6 months
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
| Group | Value | sRAGE |
|---|---|---|
| Baseline | mean 83 pmol/L | 997 pg/mL |
| 6 months | 69 pmol/L | 1125 pg/mL |
Value
Baselinemean 83 pmol/L
6 months69 pmol/L
sRAGE
Baseline997 pg/mL
6 months1125 pg/mL
- 6 months vs Baseline: P < 0.001 — decreased
- 6 months vs Baseline: P < 0.001 — increased
Observational data: associations, not effects.
Further findings
Association of change in erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) with change in NT-proBNP and sRAGE · 6 months
- Per point decrease in ESR: decrease in NT-proBNP
- 1.7-point
- Per point decrease in ESR: increase in sRAGE
- 2.2-point
- Per point decrease in CRP: NT-proBNP, sRAGE (p < 0.001)
- 1.7 and 2.7
- Larger decrease in ESR or CRP associated with larger changes in NT-proBNP and sRAGE
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scand J Rheumatol. Published 11 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →